Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Understanding human vulnerability to climate change: A global perspective on index validation for adaptation planning.
Birkmann J, Jamshed A, McMillan JM, Feldmeyer D, Totin E, Solecki W, Ibrahim ZZ, Roberts D, Kerr RB, Poertner HO, Pelling M, Djalante R, Garschagen M, Leal Filho W, Guha-Sapir D, Alegría A. Birkmann J, et al. Sci Total Environ. 2022 Jan 10;803:150065. doi: 10.1016/j.scitotenv.2021.150065. Epub 2021 Sep 1. Sci Total Environ. 2022. PMID: 34525713 Free article. Review.
Boost resilience of small and mid-sized cities.
Birkmann J, Welle T, Solecki W, Lwasa S, Garschagen M. Birkmann J, et al. Nature. 2016 Sep 29;537(7622):605-8. doi: 10.1038/537605a. Nature. 2016. PMID: 27680922 No abstract available.
Correction: Dexa-BEAM versus MIFAP as salvage regimen for recurrent lymphoma: a prospective randomized multicenter phase II trial with a median follow‑up of 14.4 years.
Kürzel S, Blaudszun AR, Stahl L, Herbst R, Kroschinsky F, Birkmann J, Hänel A, Schaefer-Eckart K, Ehninger G, Fiedler F, Bornhäuser M, Fricke S, Hänel M. Kürzel S, et al. Among authors: birkmann j. J Cancer Res Clin Oncol. 2023 Feb;149(2):929-931. doi: 10.1007/s00432-022-04324-3. J Cancer Res Clin Oncol. 2023. PMID: 36083312 No abstract available.
Dexa-BEAM versus MIFAP as salvage regimen for recurrent lymphoma: a prospective randomized multicenter phase II trial with a median follow-up of 14.4 years.
Kürzel S, Blaudszun AR, Stahl L, Herbst R, Kroschinsky F, Birkmann J, Hänel A, Schaefer-Eckart K, Ehninger G, Fiedler F, Bornhäuser M, Fricke S, Hänel M. Kürzel S, et al. Among authors: birkmann j. J Cancer Res Clin Oncol. 2022 May;148(5):1171-1181. doi: 10.1007/s00432-021-03702-7. Epub 2021 Jun 26. J Cancer Res Clin Oncol. 2022. PMID: 34176014 Clinical Trial.
59 results